Bearcat Basketball Halftime Ceremony Honors UC Recipient of "American Nobel"
Dr. Elwood Jensens research led to a discovery that transformed the treatment of breast cancer patients and saves more than 100,000 lives each year. UCs second recipient of the Lasker Award, known as the American Nobel, will be honored at a special halftime ceremony at the UC/Houston mens basketball game Saturday, Jan. 29, at Fifth Third Arena. The game begins at 7 p.m.
UC President Nancy L. Zimpher, PhD, and Senior Vice President and Provost for Health Affairs Jane E. Henney, MD, will take part in the ceremony that celebrates Dr. Jensens Lasker Award, a highly respected recognition that has honored scientific accomplishments for 56 years.
Dr. Jensen, the George J. and Elizabeth Wile Chair in Cancer Research at UC, is a distinguished university professor in the Department of Cell Biology, Neurobiology and Anatomy.
The Lasker Awards are the most coveted prize in biomedical research. Ohio has only two Lasker Award recipients, Dr. Jensen and UCs Albert Sabin, MD, who developed the worlds first oral polio vaccine.
Tags
Related Stories
Why can it get so hot at times?
September 3, 2026
Cincinnati is experiencing more days of extreme heat this summer than in previous decades, due in large part to warmer global temperatures. But explanations for these higher temperatures also relate to regional factors, including the city's location in a river valley and large proportion of built environment.
Cancer Center plays key role in lab research, clinical trials for new pancreatic cancer drug
September 1, 2026
WLWT and WCPO highlighted the contributions of University of Cincinnati Cancer Center researchers that helped lead to the recent FDA approval of daraxonrasib, a new treatment for pancreatic cancer.
Cancer Center physician receives $150,000 New Investigator Research Grant to study treatment-resistant leukemia
September 1, 2026
The University of Cincinnati Cancer Center’s Sarah Skuli, MD, PhD, received a two‑year, $150,000 Leukemia Research Foundation New Investigator Grant to study TP53‑mutated leukemia, a treatment‑resistant subtype with very poor outcomes.